Diagnostic marker found for deadly brain disease marked by dementia, movement problems. Discovery could accelerate progress toward therapies for primary tauopathies

Read also

Nightmare bacteria

«Nightmare bacteria» cases on the rise in the US: CDC

NRx Pharmaceuticals

NRx Pharmaceuticals Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product

Akari Therapeutics

Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

Breakthrough Therapy Designation To Povetacicept

Vertex: FDA Grants Breakthrough Therapy Designation To Povetacicept